Analysis of top Seeking Alpha coverage: Portola Pharmaceuticals
Today we will discuss Portola Pharmaceuticals (PTLA), which came out with some mixed news. PTLA shares were down sharply at the time of writing this note.
Portola reported that the European Medicines Agency’s ((EMA)) Committee for Medicinal Products for Human Use ((CHMP)) communicated a positive trend vote on the Marketing Authorization Application ((MAA)) for the Factor Xa-inhibitor andexant alfa. The committee though has requested Portola to provide some additional data, which is likely to delay CHMP opinion on the MAA until the fourth quarter. Andexanet